HiLIFE / Biomedicum Helsinki Seminar by Liron Bar-Peled

June 22, 2026

Date
22.06.2026
Time
13:00 - 14:00
Location
Biomedicum Helsinki 1, lecture hall 3
Organisation
HiLIFE
Contact person
hilife-seminars@helsinki.fi

HiLIFE / Biomedicum Helsinki Seminar

Identification of Druggable and Redox Vulnerabilities in Cancer

Rullo Family Endowed Chair in Cancer Research Liron Bar-Peled from the Massachusetts General Hospital and Harvard Medical School, USA will give a talk in the HiLIFE seminar series on June 22nd at 13.00-14.00. 

Liron is the Rullo Family Endowed Chair for Cancer Research at MGH and an Associate Professor of Medicine in Biological and Biomedical Sciences at Harvard Medical School. He received his Bachelor of Science degree in Biochemistry from the University of Georgia and his PhD in Biology from the Massachusetts Institute of Technology, where he used advanced cellular and molecular techniques to uncover how nutrients are sensed. As a Damon Runyon Postdoctoral fellow at the Scripps Research Institute, he leveraged chemical proteomic technologies to understand how cancer cells respond to oxidative stress. Having started his lab at the Krantz Family Center for Cancer Research, he has made important contributions to understanding how tumors sense and respond to metabolic stress and identifies new druggable vulnerabilities by integrating technologies that leverage high-throughput biochemistry, chemistry, and analytics with clinical insights.  Liron’s work led to the founding of Scorpion Therapeutics (acquired by Eli Lily) and he has been widely recognized in the field as a Pew-Stewart Scholar, Mark Foundation Emerging Leader Award, NIH/NCI Merit Award, V Foundation Scholar, MRA young investigator and Damon Runyon Innovator.

Welcome to this exciting seminar!

Pekka Katajisto

Few publications relevant to the talk: 

Weiss-Sadan T, Ge M, Hayashi M, … Bar-Peled L. NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer. Cell Metab. 2023 Mar 7;35(3):487-503.e7. doi: 10.1016/j.cmet.2023.01.012. Epub 2023 Feb 24. PMID: 36841242

Zhang J, Simpson CM, Berner J, ….Bar-Peled L. Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway. Cell. 2023 May 25;186(11):2361-2379.e25. doi: 10.1016/j.cell.2023.04.026. Epub 2023 May 15. PMID: 37192619; PMCID: PMC10225361.

Zhang J, Ali MY, Chong HB, …Bar-Peled L. Oxidation of retromer complex controls mitochondrial translation. Nature. 2025 May;641(8064):1048-1058. doi: 10.1038/s41586-025-08756-y. Epub 2025 Mar 26. PMID: 40140582; PMCID: PMC13005050.